Kenneth Alper, M.D. is an Associate Professor of Psychiatry and Neurology at the New York University School of Medicine. Dr. Alper has studied iboga from the perspective of medical ethnography, working with Howard Lotsof, the originator of the use of iboga in the treatment of substance use disorders, accessing the geographically and clinically diverse “medical subculture” to yield systematic observation on iboga in heroin detoxification, and a quantitative, descriptive overview of the global settings of iboga use. That work continues with a recent study on prospective follow-up of drug use outcomes following detoxification. Dr. Alper edited the only English language scientific text on ibogaine with Stanley Glick and Geoffrey Cordell. From the perspective of neuropharmacology, Dr. Alper’s collaborations have indicated that the mechanism of action is novel and distinct from that of the opioid receptor agonists that are the current conventional clinical standards of pharmacotherapy for opioid use disorder. His collaborations with the New York City Office of Chief Medical Examiner and the NYU Departments of Cardiology at NYU and Capital Medical University in Beijing are widely appreciated in the field of iboga treatment for advancing the effort to develop safer treatment practices.